mechlorethamine has been researched along with Bone Marrow Diseases in 16 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy." | 2.68 | High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. ( Barnett, MJ; Fairey, RN; Hogge, DE; Klasa, RJ; Klingemann, HG; Nantel, SH; Reece, DE; Shepherd, JD; Sutherland, HJ; Voss, NJ, 1995) |
| "In patients with advanced Hodgkin's disease (HD), the alternation of MOPP with ABVD or hybrid MOPP/ABVD are associated with a high CR rate and a high probability of 5-year survival." | 1.29 | Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. ( Aversa, S; Bianco, A; Chiarion Sileni, V; Fiorentino, MV; Mazzarotto, R; Pappagallo, GL; Salvagno, L; Scarzello, G; Sorarù, M; Sotti, G, 1995) |
| "A patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described." | 1.28 | Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases? ( Nikolaou, N; Orfanos, S; Pavlidis, N; Tolis, C; Tolis, G, 1989) |
| " The planned dosage intensity had to be significantly reduced in over half of the patients because of marrow toxicity." | 1.26 | Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. ( Dawson, AA; Fell, LF; Green, JA; Murray, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (81.25) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| GOLL, KH | 1 |
| MRAZEK, RG | 1 |
| WACHOWSKI, TJ | 1 |
| KIRCHMAIR, H | 1 |
| Andrieu, JM | 1 |
| Cramer, P | 1 |
| Asselain, B | 1 |
| Tea, N | 1 |
| Tricot, G | 1 |
| Flandrin, G | 1 |
| Jacquillat, C | 1 |
| Bernard, J | 1 |
| Fiacchini, M | 1 |
| Lauria, F | 1 |
| Mazza, P | 1 |
| Tura, S | 1 |
| Green, JA | 1 |
| Dawson, AA | 1 |
| Fell, LF | 1 |
| Murray, S | 1 |
| Salvagno, L | 1 |
| Sorarù, M | 1 |
| Sotti, G | 1 |
| Aversa, S | 1 |
| Chiarion Sileni, V | 1 |
| Mazzarotto, R | 1 |
| Scarzello, G | 1 |
| Bianco, A | 1 |
| Pappagallo, GL | 1 |
| Fiorentino, MV | 1 |
| Reece, DE | 1 |
| Barnett, MJ | 1 |
| Shepherd, JD | 1 |
| Hogge, DE | 1 |
| Klasa, RJ | 1 |
| Nantel, SH | 1 |
| Sutherland, HJ | 1 |
| Klingemann, HG | 1 |
| Fairey, RN | 1 |
| Voss, NJ | 1 |
| Ben-Ishay, Z | 1 |
| Farber, E | 1 |
| Hovgaard, DJ | 1 |
| Nissen, NI | 1 |
| Pavlidis, N | 1 |
| Nikolaou, N | 1 |
| Tolis, C | 1 |
| Orfanos, S | 1 |
| Tolis, G | 1 |
| Fairley, GH | 1 |
| Ultmann, JE | 1 |
| Nixon, DD | 1 |
| Currey, HL | 1 |
| Finklestein, JZ | 1 |
| Ekert, H | 1 |
| Isaacs, H | 1 |
| Higgins, G | 1 |
| Sharp, JG | 1 |
| Thomas, DB | 1 |
2 reviews available for mechlorethamine and Bone Marrow Diseases
| Article | Year |
|---|---|
The therapy of lymphoma.
Topics: Adrenal Cortex Hormones; Asparaginase; Bone Marrow Diseases; Chlorambucil; Cyclophosphamide; Cytarab | 1969 |
Treatment of rheumatoid arthritis with cytotoxic and antimetabolic drugs.
Topics: Alopecia; Aminopterin; Antimetabolites; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; | 1970 |
3 trials available for mechlorethamine and Bone Marrow Diseases
| Article | Year |
|---|---|
High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bo | 1995 |
Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Dose- | 1992 |
Treatment of rheumatoid arthritis with cytotoxic and antimetabolic drugs.
Topics: Alopecia; Aminopterin; Antimetabolites; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; | 1970 |
12 other studies available for mechlorethamine and Bone Marrow Diseases
| Article | Year |
|---|---|
[Panmyelophthisis following treatment with tri (beta-chloräthyl) amine hydrochloride (trimitan)].
Topics: Amines; Bone Marrow; Bone Marrow Diseases; Hematologic Diseases; Mechlorethamine; Nitrogen Mustard C | 1954 |
Hematopoietic depression from nitrogen mustard and triethylene melamine.
Topics: Bone Marrow; Bone Marrow Diseases; Depression; Depressive Disorder; Hematopoietic System; Mechloreth | 1955 |
[Fatal panmyelopathy under combined therapy with roentgen rays and nitrogen mustard (mitomem)].
Topics: Bone Marrow; Bone Marrow Diseases; Mechlorethamine; Nitrogen Mustard Compounds; Radiation Injuries; | 1960 |
Chemotherapy-radiotherapy versus chemotherapy in Hodgkin's disease with bone marrow involvement. Retrospective analysis of 32 cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child | 1981 |
[Clinical and hematological characteristics and MOPP tolerance of patients with Hodgkin's lymphoma in the bone marrow].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Drug | 1982 |
Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Bon | 1980 |
Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1995 |
Protective effects of an inhibitor of protein synthesis, cycloheximide, on bone marrow damage induced by cytosine arabinoside or nitrogen mustard.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Bone Marrow Diseases; Cycloheximide; Cytarabine; Erythropoi | 1975 |
Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Hodgkin Dis | 1989 |
The treatment of Hodgkin's disease.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Marrow Diseases; Chlorambucil; Drug Combinations; Hodgk | 1972 |
Bone marrow metastases in children with solid tumors.
Topics: Bone Marrow Diseases; Bone Marrow Examination; Bone Neoplasms; Child; Cyclophosphamide; Dactinomycin | 1970 |
Patterns of damage and regeneration in the murine lymphomyeloid complex following single intravenous doses of mustine hydrochloride.
Topics: Animals; Bone Marrow Diseases; Injections, Intravenous; Leukocytes; Lymphatic Diseases; Mechloretham | 1970 |